Braf
A gene whose mutations drive several cancers; a major target for precision drugs.
If Braf is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Population-based Multicenter Real-world outcomes of Encorafenib plus Panitumumab in BRAF V600E-mutated Metastatic Colorectal Cancer · Clinical Colorectal Cancer · 2026-09-03
- Therapy-Induced Metastatic Melanoma During Treatment With Encorafenib and Cetuximab for BRAF-Mutated Colorectal Cancer: A Case Report and Short Literature Review · Clinical Colorectal Cancer · 2026-09-01
- First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial. · Signal Transduct Target Ther · 2026-09-01
- BRAF V600E-Mutated Metastatic Colorectal Cancer: Practical Management in the Post-BREAKWATER Era. · J Gastrointest Cancer · 2026-08-31
- Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial · Journal of Clinical Oncology · 2026-08-30
- WNT-driven immune evasion promotes malignant transformation of BRAF-mutant colorectal cancer. · Gastroenterology · 2026-08-18
What the reporting says
It shows up alongside Colorectal Cancer (75), Braf V600e (34), Egfr (24 — acquisition ×2), Immunotherapy (18), KRAS (18 — acquisition ×2), ctDNA (9), Lung Cancer (9 — acquisition ×2), Her2 (8).
Two steps out: Wang (through Colorectal Cancer, 59 shared stories on the weaker link); MSI-H (through Colorectal Cancer, 57 shared stories on the weaker link); Zhang (through Colorectal Cancer, 50 shared stories on the weaker link); Chen (through Colorectal Cancer, 46 shared stories on the weaker link).
Tracked since Mar 15, with coverage on 71 separate days — concentrated in Oncology and Pubmed Targeted.